Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

Alexey Fomin, MD, & W. Neal Roberts, MD  |  Issue: October 2016  |  

As further apparent differences between different populations emerge, investigators will have to look to genetics, epigenetic and microbiome differences to explain different response rate for different population groups.11 Clinical readers of studies will have to continue to ask two questions: Do the data support the conclusion (as they do, by and large, for all the studies considered here)? And are these study patients the same as our patients?

Alexey Fomin, MD, is a second-year rheumatology fellow at the University of Louisville in Kentucky.

ADVERTISEMENT
SCROLL TO CONTINUE

W. Neal Roberts, MD, is program director and head of the rheumatology division at the University of Louisville.

References

  1. Liao R, Liu Q, Zheng Z, et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015;10(7):e0132724.
  2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931–940.
  3. Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305–1313.
  4. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–1286.
  5. Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 Jan;28(1):106–111.
  6. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–1226.
  7. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18–26.
  8. Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30–36.
  9. Gómez-Puerta JA, Barbhaiya M, Guan H, et al. Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus: A Hispanic and Asian paradox. Arthritis Rheumatol. 2015 Mar;67(3):752–760.
  10. Yap DY, Ma MK, Mok MM, et al. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford). 2014;53(12):2232–2237.
  11. Tiniakou E, Costenbader KH, Kriegel MA. Sex-specific environmental influences on the development of autoimmune diseases. Clin Immunol. 2013 Nov;149(2):182–191.

Related Articles